Advanced search
Publication Cover
Renal Failure Volume 15, 1993 - Issue 2
Submit an article Journal homepage
4
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Lithium Clearance Measurements During Recombinant Interleukin 2 Treatment: Tubular Dysfunction in Man

Steven D. Heys Department of Surgery, Pathology University of Aberdeen, Aberdeen, Scotland
,
Oleg Eremin Department of Surgery, Pathology University of Aberdeen, Aberdeen, Scotland
,
Christopher R. Franks EuroCetus B.V., Paasheuvelweg 30, 1105J, Amsterdam, The Netherlands
,
John Broom Department of Chemical, Pathology University of Aberdeen, Aberdeen, Scotland
&
Paul H. Whiting Department of Chemical, Pathology University of Aberdeen, Aberdeen, Scotland
Pages 195-201 | Published online: 07 Jul 2009

References

  • Lotze M. T., Chang A. E., Seipp C. A., Simpson C., Vetto J. T., Rosenberg SA. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment of patients with disseminated findings. J Am Med Assoc 1986; 256: 3117–3124
  • Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Lehman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T., Seipp C. A., Simpson C. G., White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889–905
  • Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–485
  • Rosenberg S. A., Lotze M. T., Muul L. M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with meta-static cancer. N Engl J Med 1985; 313: 1485–1492
  • Lotze M. T., Matory Y. L., Rayner A. A., Ettinghausen S. E., Vetto J. T., Seipp C. A., Rosenberg SA. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–2722
  • Belldegrun A., Webb D. E., Austin H. A., Steinberg S. M., White D. E., Linehan W. M., Rosenberg SA. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann lnt Med 1987; 106: 817–822
  • Thomsen K., Lithium clearance. A new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984; 37: 217–223
  • Koomans H. A., Boer W. H., Dorhour-Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989; 36: 2–12
  • Duncan J. I., Heys S. D., Thomson A. W., Simpson J. G., Whiting PH. Influence of the hepatic drug-metabolizing enzyme inducer phenobarbitone on cyclosporine nephrotoxicity and hepato-toxicity in renal allografted rats. Transplantation 1988; 45: 693–697
  • Kozeny G. A., Nicolas J. D., Creekmore S., Sticklin L., Hano JE, Fisher RI. Effects of Interleukin-2 immunotherapy on renal function. J Clin Oncol 1988; 6: 1170–1176
  • Sosman J. A., Kohler P. C., Hank J. A., Moore K. H., Bechhofer R., Storer B., Sondel PM. Repetitive weekly cycles of interleukin-2. II. Clinical and immunological effects of dose schedule, and addition of indomethacin. J Natl Cancer Inst 1988; 80: 1451–1461
  • Webb D. E., Austin H. A., Belldegrun A., Vaughan E., Linehan W. M., Rosenberg SA. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988; 30: 141–145
  • Textor S. C., Margolin K., Blayney D., Carlson J., Doroshow J. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. Am J Med 1987; 83: 1055–1061
  • Boer W. H., Koomans H. A., Dorhout Mees EJ. Lithium clearance in healthy humans suggesting reabsorption beyond the proximal tubules. Kidney Int 1990; 37((Suppl 28))S39–S44
  • Rosenstein M., Ettinghausen S. E., Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735–1742
  • Shalmi C. L., Dutcher J. P., Feinfeld D. A., Chun K. J., Soleemi K. R., Freeman L. M., Lynn R. I., Wiernik PH. Acute renal dysfunction during Interleukin-2 treatment: Suggestion of an intrinsic renal lesion. J Clin Oncol 1990; 8: 1839–1846
  • Clive D. M., Stoff JS. Renal syndromes associated with non-steroidal antiinflammatory drugs. N Engl J Med 1984; 310: 563–572
  • Kramer H. J., Glanzer K., Dusing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int 1981; 19: 851–859
  • Christiansen N. P., Skubitz K. M., Nath K., Ochoa A., Kennedy BJ. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. Am J Med 1988; 84: 1072–1075

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.